Indication | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Pivotal | Collaboration Partner |
---|---|---|---|---|---|---|---|
Iopofosine |
Waldenstrom macroglobulinemia (WM) |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Pivotal Phase in progress
|
|
Highly Refractory Multiple Myeloma |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Pivotal Phase not-started
|
||
Pediatric |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
||
Head & Neck (IIS) |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
||
CLR 1900 |
Solid Tumors |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
|
CLR 2000 |
Solid Tumors |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
|
CLR 12120 |
Solid Tumors |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
|
New PDC's |
Various targets |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
|
Various targets |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|